Presently, Anthony Adam Rosenberg is Chairman of Oculis SA, Chairman of Cullinan Oncology LLC, Chairman at Cullinan Oncology, Inc., Chief Executive Officer at TR Advisory Services GmbH and Senior Advisor at Kurma Partners SA. Mr. Rosenberg is also on the board of argenx SE, SiO2 Medical Products, Inc. and Cullinan Mica Corp.

Mr. Rosenberg previously was Head-Mergers, Acquisitions & Licensing at Novartis AG and Global Head-Business Development & Licensing at Novartis Pharmaceuticals Corp. (a subsidiary of Novartis AG) and Managing Director at MPM Capital Inc.

Mr. Rosenberg received an undergraduate degree from the University of Leicester and a graduate degree from the University of London.